PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsSucralfate
Sucralfate
Carafate, Sucralfate (sucralfate) is an unknown pharmaceutical. Sucralfate was first approved as Carafate on 1982-01-01. It is used to treat duodenal ulcer, esophagitis, gastritis, pneumonia, and stomach ulcer amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
stomatognathic diseasesD009057
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Carafate (generic drugs available since 1996-03-29)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sucralfate
Tradename
Company
Number
Date
Products
CARAFATEAbbVieN-018333 RX1982-01-01
1 products, RLD, RS
CARAFATEAbbVieN-019183 RX1993-12-16
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
varecell intensive liposome doublecreamunapproved drug other2021-09-07
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
A02: Drugs for acid related disorders
A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
A02BX: Other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) in atc
A02BX02: Sucralfate
HCPCS
No data
Clinical
Clinical Trials
213 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DyspepsiaD004415EFO_0008533K30112
Liver neoplasmsD008113EFO_1001513C22.0112
Opioid-related disordersD009293EFO_0005611F1111
Ventilator-associated pneumoniaD053717EFO_1001865J95.85111
Coronary artery diseaseD003324I25.111
GastritisD005756EFO_0000217K29.711
Umbilical herniaD006554K4211
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Head and neck neoplasmsD00625822
AnxietyD001007EFO_0005230F41.1112
MucositisD052016EFO_100189811
Esophageal neoplasmsD004938C1511
Mediastinal neoplasmsD008479C38.311
Oropharyngeal neoplasmsD00995911
Laryngeal neoplasmsD007822EFO_0003817C3211
Indications Phases 2
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E1111
Eosinophilic esophagitisD057765EFO_0004232K20.011
Spinal cord injuriesD013119EFO_100191911
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PainD010146EFO_0003843R5277
StrokeD020521EFO_0000712I63.966
Rotator cuff injuriesD000070636M75.155
Low back painD017116HP_0003419M54.555
Pelvic painD01769944
Shoulder painD020069HP_0030834M25.5144
FatigueD005221HP_0012378R53.8344
Gastroesophageal refluxD005764EFO_0003948K2133
Postoperative painD010149G89.1833
Neck painD019547HP_0030833M54.233
Show 120 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSucralfate
INNsucralfate
Description
Sucralfate, sold under various brand names, is a medication used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers. Its usefulness in people infected by H. pylori is limited. It is used by mouth (for upper GIT ulcers) and rectally (for radiation proctitis).
Classification
Small molecule
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O=S(=O)(OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O)O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O
Identifiers
PDB
CAS-ID54182-58-0
RxCUI
ChEMBL IDCHEMBL3989780
ChEBI ID
PubChem CID6398525
DrugBankDB00364
UNII IDXX73205DH5 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
Carafate Allergan
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Carafate Warner Chilcott
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Sucralfate
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 14,383 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,700 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use